XNCRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Xencor Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$23.19+0.34 (+1.49%)
Close on Oct 19, 2026
- Market cap
- $1.76B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Operating margin
-141.4%−78.8 pts over 5 years
Net margin
-73.2%−16.7 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +13.7% | -8.6% | +0.5% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 18.0% | -11.9% | -14.0% | |
| Return on assets | 14.2% | -10.1% | -10.1% | |
| Current ratio | 1.33 | 5.27 | 6.25 | |
| Debt to equity | – | – | 0.19 | |
| Net debt to EBITDA | – | – | -0.39× | |
| Interest coverage | 2097.1× | – | -5.6× | |
| Capex to revenue | 1.4% | 8.6% | 2.5% | |
| Diluted shares | 42M | 57M | 74M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Xencor generated $456.57M from operations and spent $79.49M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$456.57M
Used
$79.49M
Capital expenditure$79.49M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-73.2%
×Asset turnover0.14×
×Equity multiplier1.39×
=Return on equity, FY2025-14.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -73.2% | 0.14× | 1.39× | -14.0% |
| FY2024 | -210.5% | 0.12× | 1.43× | -34.7% |
| FY2023 | -76.2% | 0.19× | 1.30× | -19.2% |
| FY2022 | -33.5% | 0.20× | 1.15× | -7.6% |
| FY2021 | 30.0% | 0.36× | 1.18× | 12.7% |
| FY2020 | -56.5% | 0.18× | 1.18× | -11.9% |
| FY2019 | 17.2% | 0.25× | 1.12× | 4.8% |
| FY2018 | -173.4% | 0.08× | 1.15× | -16.8% |
| FY2017 | -83.4% | 0.11× | 1.25× | -11.8% |
| FY2016 | 41.4% | 0.34× | 1.27× | 18.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$91.92M
- Cash generatingOperating cash flow above zero-$135.12M
- Return on assets improvedROA up on the prior year-24.1% → -9.7%
- Earnings backed by cashOperating cash flow above net income-$135.12M vs -$91.92M
- Less leverageLong-term debt to assets fell12.1% → 8.7%
- Better liquidityCurrent ratio rose6.61 → 6.25
- No dilutionShare count did not rise65M → 74M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.11 → 0.13